These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25939484)

  • 1. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.
    Krintel SB; Dehlendorff C; Hetland ML; Hørslev-Petersen K; Andersen KK; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard HM; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Jørgensen A; Raun J; Ammitzbøll CG; Østergaard M; Stengaard-Pedersen K; Johansen JS
    Pharmacogenomics J; 2016 Apr; 16(2):141-6. PubMed ID: 25939484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.
    Sode J; Krintel SB; Carlsen AL; Hetland ML; Johansen JS; Hørslev-Petersen K; Stengaard-Pedersen K; Ellingsen T; Burton M; Junker P; Østergaard M; Heegaard NHH
    J Rheumatol; 2018 Jan; 45(1):53-61. PubMed ID: 29142030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
    Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
    Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.
    Castro-Villegas C; Pérez-Sánchez C; Escudero A; Filipescu I; Verdu M; Ruiz-Limón P; Aguirre MA; Jiménez-Gomez Y; Font P; Rodriguez-Ariza A; Peinado JR; Collantes-Estévez E; González-Conejero R; Martinez C; Barbarroja N; López-Pedrera C
    Arthritis Res Ther; 2015 Mar; 17(1):49. PubMed ID: 25860297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
    N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL
    J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
    Lovell DJ; Ruperto N; Goodman S; Reiff A; Jung L; Jarosova K; Nemcova D; Mouy R; Sandborg C; Bohnsack J; Elewaut D; Foeldvari I; Gerloni V; Rovensky J; Minden K; Vehe RK; Weiner LW; Horneff G; Huppertz HI; Olson NY; Medich JR; Carcereri-De-Prati R; McIlraith MJ; Giannini EH; Martini A; ;
    N Engl J Med; 2008 Aug; 359(8):810-20. PubMed ID: 18716298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
    Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
    J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate.
    Torrance GW; Tugwell P; Amorosi S; Chartash E; Sengupta N
    Rheumatology (Oxford); 2004 Jun; 43(6):712-8. PubMed ID: 15039494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
    Axelsen MB; Eshed I; Hørslev-Petersen K; Stengaard-Pedersen K; Hetland ML; Møller J; Junker P; Pødenphant J; Schlemmer A; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Krogh NS; Johansen JS; Østergaard M;
    Ann Rheum Dis; 2015 May; 74(5):867-75. PubMed ID: 24412895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
    Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
    Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study.
    van Vollenhoven RF; Cifaldi MA; Ray S; Chen N; Weisman MH
    Arthritis Care Res (Hoboken); 2010 Feb; 62(2):226-34. PubMed ID: 20191522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.
    Harigai M; Takeuchi T; Tanaka Y; Matsubara T; Yamanaka H; Miyasaka N
    Mod Rheumatol; 2012 Nov; 22(6):814-22. PubMed ID: 22270346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.
    Feuchtenberger M; Kleinert S; Scharbatke EC; Gnann H; Behrens F; Wittig BM; Greger G; Tony HP
    Clin Exp Rheumatol; 2015; 33(3):321-9. PubMed ID: 25897681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.